National Cancer Institute (U.S.)

• 

  Subject Areas on Research

  • A Proposed System Toward Standardizing Surgical-Based Treatments for Malignant Pleural Mesothelioma, From the Joint National Cancer Institute-International Association for the Study of Lung Cancer-Mesothelioma Applied Research Foundation Taskforce. 
  • A year of successful cancer vaccines points to a path forward. 
  • Accessibility and Barriers to Oncology Appointments at 40 National Cancer Institute-Designated Comprehensive Cancer Centers: Results of a Mystery Shopper Project. 
  • Adult primitive neuroectodermal tumors: the prognostic value of supratentorial location. 
  • Advanced neoplasia in Veterans at screening colonoscopy using the National Cancer Institute Risk Assessment Tool. 
  • American Society of Clinical Oncology statement: achieving high-quality cancer survivorship care. 
  • Associations of prostate cancer risk variants with disease aggressiveness: results of the NCI-SPORE Genetics Working Group analysis of 18,343 cases. 
  • Benchmark Credentialing Results for NRG-BR001: The First National Cancer Institute-Sponsored Trial of Stereotactic Body Radiation Therapy for Multiple Metastases. 
  • COVID-19 Challenges Confronted by Smoking Cessation Clinical Trials for People Living With HIV: The Experience of Grantees of the US National Cancer Institute. 
  • Cancer Informatics for Cancer Centers (CI4CC): Building a Community Focused on Sharing Ideas and Best Practices to Improve Cancer Care and Patient Outcomes. 
  • Cancer Moonshot Data and Technology Team: Enabling a National Learning Healthcare System for Cancer to Unleash the Power of Data. 
  • Challenges to accrual predictions to phase III cancer clinical trials: a survey of study chairs and lead statisticians of 248 NCI-sponsored trials. 
  • Cognitive Interview-Based Validation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in Adolescents with Cancer. 
  • Cognitive interviewing of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). 
  • Communicating Research to Non-Researcher Audiences: A Panel Discussion From the National Cancer Institute's Future of Cancer Health Economics Research Conference. 
  • Comparative effectiveness research in cancer genomics and precision medicine: current landscape and future prospects. 
  • Compliance With Price Transparency Rules at US National Cancer Institute-Designated Cancer Centers. 
  • Composite grading algorithm for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). 
  • Consensus report of a joint NCI thoracic malignancies steering committee: FDA workshop on strategies for integrating biomarkers into clinical development of new therapies for lung cancer leading to the inception of "master protocols" in lung cancer. 
  • Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. 
  • Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. 
  • Determining the predictors of innovation implementation in healthcare: a quantitative analysis of implementation effectiveness. 
  • Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). 
  • Effect of surgeon specialization on long-term survival following colon cancer resection at an NCI-designated cancer center. 
  • Evaluation of different recall periods for the US National Cancer Institute's PRO-CTCAE. 
  • Factors associated with biomedical research participation within community-based samples across 3 National Cancer Institute-designated cancer centers. 
  • Feasibility of Patient Reporting of Symptomatic Adverse Events via the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a Chemoradiotherapy Cooperative Group Multicenter Clinical Trial. 
  • Gene-environment interactions in cancer epidemiology: a National Cancer Institute Think Tank report. 
  • Genomic Classification of Cutaneous Melanoma. 
  • Health-related quality of life and symptom management research sponsored by the National Cancer Institute. 
  • High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. 
  • Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting. 
  • Impact of cancer center accreditation on outcomes of patients undergoing resection for hepatocellular carcinoma: A SEER-Medicare analysis. 
  • Implementing survivorship care plans for colon cancer survivors 
  • Infrastructure to Support Accrual of Older Adults to National Cancer Institute Clinical Trials. 
  • Interrater Reliability in Toxicity Identification: Limitations of Current Standards. 
  • Interventions to improve the quality of life and survivorship of older adults with cancer: The funding landscape at NIH, ACS and PCORI. 
  • Is mortality due to primary malignant brain and other central nervous system tumors decreasing? 
  • Mapping child and adolescent self-reported symptom data to clinician-reported adverse event grading to improve pediatric oncology care and research. 
  • Measuring Aging and Identifying Aging Phenotypes in Cancer Survivors. 
  • Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). 
  • NCI, NHLBI first international consensus conference on late effects after pediatric hematopoietic cell transplantation: state of the science, future directions. 
  • National Cancer Institute Patient Navigation Research Program: methods, protocol, and measures. 
  • National Cancer Institute Prostate Cancer Genetics Workshop. 
  • National Cancer Institute, National Heart, Lung and Blood Institute/Pediatric Blood and Marrow Transplantation Consortium First International Consensus Conference on late effects after pediatric hematopoietic cell transplantation: the need for pediatric-specific long-term follow-up guidelines. 
  • Oncology Nursing Symptom Science: Overview of the NINR, ONS, and NCI Symptom Science Colloquium. 
  • Ontario Cancer Research Ethics Board: lessons learned from developing a multicenter regional institutional review board. 
  • Organizational and physician factors associated with patient enrollment in cancer clinical trials. 
  • Partnership for defining the impact of 12 selected rare CNS tumors: a report from the CBTRUS and the NCI-CONNECT. 
  • Patient-reported outcomes assessment in cancer trials: evaluating and enhancing the payoff to decision making. 
  • Patterns of Long-term Cancer Survivorship Care in a National Cancer Institute-Designated Comprehensive Cancer Center. 
  • Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology Group. 
  • Preliminary findings from a clinical demonstration project for veterans returning from Iraq or Afghanistan. 
  • Promoting patient safety through peer review. 
  • Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee - International Association for the Study of Lung Cancer - Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting. 
  • Rationale of technical requirements for NRG-BR001: The first NCI-sponsored trial of SBRT for the treatment of multiple metastases. 
  • Recommendations for high-priority research on cancer-related fatigue in children and adults. 
  • Recommended patient-reported core set of symptoms and quality-of-life domains to measure in ovarian cancer treatment trials. 
  • Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials. 
  • Recommended patient-reported core set of symptoms to measure in head and neck cancer treatment trials. 
  • Recommended patient-reported core set of symptoms to measure in prostate cancer treatment trials. 
  • Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials. 
  • Report of National Brain Tumor Society roundtable workshop on innovating brain tumor clinical trials: building on lessons learned from COVID-19 experience. 
  • State of the Art: Toward Improving Outcomes of Lung and Liver Tumor Biopsies in Clinical Trials-A Multidisciplinary Approach. 
  • Survivorship care plans in research and practice. 
  • Sustainability and performance of the National Cancer Institute's Community Clinical Oncology Program. 
  • The National Cancer Institute-American Society of Clinical Oncology Cancer Trial Accrual Symposium: summary and recommendations. 
  • The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes. 
  • The United States National Cancer Institute's Coordinated Research Effort on Tobacco Use as a Major Cause of Morbidity and Mortality among People with HIV. 
  • The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma: Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. 
  • Toward Improving Practices for Submission of Diagnostic Tissue Blocks for National Cancer Institute Clinical Trials. 
  • Toward a Shared Vision for Cancer Genomic Data. 
  • Transforming epidemiology for 21st century medicine and public health. 
  • Utilization and impact of immunotherapy in stage IV melanoma using the National Cancer Database. 
  • Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). 
  • ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper.